News Daily News Reduction in BP Drives Treatment Preference for Hypertensive Patients Michael O'Riordan December 20, 2022
News Conference News AHA 2022 SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint Todd Neale November 09, 2022
Presentation AHA 2022 Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial Presenter: David E. Kandzari November 07, 2022
News Conference News TCT 2022 SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss Michael O'Riordan September 19, 2022
News Opinion Editor's Corner EuroPCR 2022 EuroPCR Kicks Off In Person Next Week in Paris: Here’s What to Expect Shelley Wood May 12, 2022
News Conference News ACC 2022 SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures Todd Neale April 08, 2022
Presentation ACC 2022 Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial Presenter: Felix Mahfoud April 04, 2022